Pleased pe a plus sign (+) inside this box →

TFU \$

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	•		Application Number	10/697,828		
			Filing Date	October 29, 2003		
	TRANSMITTAL	_	First Named Inventor	ROSEN, STEVEN D.		
	FORM		Group Art Unit	1645		
	(to be used for all correspondence after ini	tial filing)	Examiner Name	To Be Assigned		
	Total Number of Pages in This Submissi	on	Attorney Docket Number	UCAL-138DIV		
			ES (check all that apply)			
	Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Documents Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	(for an Drawin Dr	ing-related Papers on to Convert to a cional Application of Attorney, Revocation ge of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 1) Petition to Expunge Information (1 pg.) 2) PTO/SB/08A (1 pg.) 3) Return Postcard		
	SIGNA	TUDE OF ADDI	ICANT ATTORNEY OF	ACENT		
Signing Attorney/Agent (Reg. No.) PAULA A. BORDEN, 42,344 BOZICEVIC, FIELD & FRANCIS LLP Signature June 8, 2004						
CERTIFICATE OF HAND DELIVERY						
I hereby	certify that this correspondence is being d	eposited via hand d	lelivery to the U.S. Patent and T	rademark Office		
Typed c Signatu	or printed name HANH	DINH		Date June 10, 2004		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ifv.

CERTIFICATE OF HAND DELIVERY I hereby certify that this correspondence is being deposited via hand delivery to the U.S. Patent and Trademark Office Typed or Printed Name N. DINH HANH Signature dinh Date June 10,2004 Attorney Docket UCAL-138DIV To Be Assigned (Confirmation No.) PETITION UNDER 37 CFR §1.59(b) **Application Number** 10/697,828 TO EXPUNGE INFORMATION IN THE Filing Date October 29, 2003 APPLICATION FILE ROSEN, STEVEN First Named Inventor Examiner To Be Assigned ommissioner for Patents PO Box 1450 Group Art Unit To Be Assigned Alexandria, VA 22313 Title NOVEL GLYCOSYL SULFOTRANSFERASES GST-4 ALPHA, GST-4BETA, & GST-6

Sir:

This is a Petition under 37 C.F.R.§1.59(b), which Petition is being filed concurrently with an Information Disclosure Statement (IDS) and PTO form SB/08A. As provided for under 37 C.F.R.§1.59(b), Applicants respectfully request that the Office expunge and return the information that is indicated as proprietary and that is included in the IDS being filed herewith.

The accompanying IDS contains information that is proprietary. The proprietary information was hand delivered to Technology Center 1600. The proprietary information in the accompanying IDS has been labeled as such. To the best of our knowledge, the proprietary material has not been made public. The proprietary information will be retained by the petitioner for the period of any patent with regard to which the information is submitted. This Petition to Expunge is being submitted on behalf of the party who originally submitted the proprietary information.

The \$130.00 fee set forth in 37 C.F.R. §1.17(h) to cover the petition accompanies this Petition. The Commissioner is hereby authorized to charge fees associated with the filing of this petition, and any additional 06/15fees which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order 01 Feminater UCAL-138 DIV. 19697928

06/15/2004 HALI11

00000094 10697828

01 FC:1460

130.00 DA

Date:

June 8, 2004

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Paula A. Borden Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200

Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

CERTIFICATE OF HAND DELIVERY Lhereby certify that this correspondence is being deposited via hand delivery to Technology Center 1600 of the U.S. Patent and Trademark Office Typed or Printed Name DINH HANH Signature Date June 10,2004 Attorney Docket **UCAL-138DIV INFORMATION** First Named Inventor ROSEN, STEVEN **DISCLOSURE STATEMENT Application Number** 10/697,828 Confirmation No. To Be Assigned Filing Date October 29, 2003 Address to: **Group Art Unit** To Be Assigned Commissioner for Patents **Examiner Name** To Be Assigned P.O. Box 1450 Alexandria, VA 22313-1450 "NOVEL GLYCOSYL SULFOTRANSFERASES Title: GST-4 ALPHA, GST-4BETA, & GST-6"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

Incyte Lifeseq clone numbers 1846903; 3219891; 3372492; 3373406: 3126392; 6869651; and GenBank accession numbers AA 261202; AI 282873; AC 009105; AC 009163; AC 011934; AC 025287; AC 026419; and AF 176838 were disclosed under Example 1, Cloning of GST-4, beginning at page 41. Incyte Lifeseq clone number 0182182 and GenBank accession numbers AI 528511 and AC 010547 were disclosed under Example 2, Cloning of GST-6, beginning at page 45.

Pursuant to M.P.E.P. section 724.02, Applicants submit concurrently (via hand delivery to Technology Center 1600) in an envelope marked as proprietary that contains the nucleic acid sequence for the following:

Incyte Lifeseq clone no.3373406; Incyte Lifeseq clone no.3372492; Incyte Lifeseq clone no.3126392; Incyte Lifeseq clone no.3219891; Incyte Lifeseq clone no.1846903; Incyte Lifeseq clone no.6869651; and Incyte Lifeseq clone no.0182182.

USSN: 10/697,828 Docket No.: UCAL-138DIV

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As Applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCAL-138DIV may be charged thereon.

Date: June 8, 2004

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Paula A. Borden

Registration No. 42,344

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number,

tute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known					
Application Number	10/697,828				
Filing Date	October 23, 2003				
First Named Inventor	ROSEN				
Group Art Unit	To Be Assigned				
Examiner Name	To Be Assigned				
Attorney Docket Number	UCAL-138DIV				

U.S. PATENT DOCUMENTS								
Examin er Initials'	Cite No. ¹	U.S. Pate Number	ent Documents Kind Code ² (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No. ¹	Foreign Patent Documents		ocuments	Name of Patentee or	Date of Publication	Pages, Columns, Lines,	
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	lo. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		Incyte Lifeseg clone no.3373406				
		Incyte Lifeseg clone no.3372492				
		Incyte Lifeseg clone no.3126392				
		Incyte Lifeseg clone no.3219891				
		Incyte Lifeseg clone no.1846903				
		Incyte Lifeseg clone no.6869651				
		Incyte Lifeseg clone no.0182182				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.